Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide

International Journal of Pharmaceutics

Volumn 360, Issue 1-2, 2008, Pages 213-218

  Sanganwar, Ganesh P ^a   Gupta, Ram B ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Adsorption; Dissolution rate enhancement; Fenofibrate; Poorly water soluble drugs; Silica; Supercritical carbon dioxide

Indexed keywords

CARBON DIOXIDE; FENOFIBRATE; SILICON DIOXIDE; SUPERCRITICAL CARBON DIOXIDE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; IMAGE ANALYSIS; INFRARED SPECTROSCOPY; PRESSURE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

ANTILIPEMIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBON DIOXIDE; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG STABILITY; HYDROGEN BONDING; KINETICS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; PROCETOFEN; SILICON DIOXIDE; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 47049131872     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.04.041     Document Type: Article

References (38)

1. Aguiar A.J., Zelmer A.W., and Kinkel A.W. Deaggregation behavior of a relatively insoluble substituted benzoic acid and its sodium salt. J. Pharm. Sci. 56 (1967) 1243-1252
2. Aigner Z., Bencz I., and Kata M. Increasing the solubility characteristics of fenofibrate with cyclodextrin. J. Inclusion Phenomena Mol. Recognit. Chem. 20 (1995) 1-252
3. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
4. Cabot Corp., 2007. Applications of CAB-O-SIL M-5P fumed silica in formulation and design of solid dosage forms. Available via www.cabot-corp.com (accessed on June 20, 2007).
5. Cabot Corp., 2007. Functions of CAB-O-SIL fumed silica in pharmaceutical applications. Available via www.cabot-corp.com (accessed on June 20, 2007).
6. Cabot Corp., 2007. Properties of CAB-O-SIL M-5P fumed silica. Available via www.cabot-corp.com (accessed on June 20, 2007).
7. Charnay C., Begu S., Tourne-Peteilh C., Nicole L., Lerner D.A., and Devoisselle J.M. Inclusion of ibuprofen in mesoporous templated silica:drug loading and release property. Eur. J. Pharm. Biopharm. 57 (2004) 533-540
8. Corrigan O.I., and Holohan E.M. Amorphous spray-dried hydroflumethiazide-polyvinylpyrrolidone systems: physicochemical properties. J. Pharm. Pharmacol. 36 (1984) 217-221
9. Costa P., and Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm Sci. 13 (2001) 123-133
10. Finholt P., and Slovang S. Dissolution kinetics of drugs in human gastric juice the role of surface tension. J. Pharm. Sci. 57 (1968) 1322-1326
11. Friedrich H., Fussnegger B., Kolter K., and Bodmeier R. Dissolution rate improvement of poorly water soluble drugs obtained by adsorbing solutions of drugs in solvents onto high surface area carriers. Eur. J. Pharm. Biopharm. 62 (2006) 171-177
12. Froster A., Hempenstall J., and Rades T. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with amorphous polymers. J. Pharm. Pharmacol. 53 (2001) 303-315
13. Gupta R.B., and Shim J.J. Solubility in Supercritical Carbon Dioxide (2007), Taylor and Francis Group, New York
14. Hancock B.C., and Zorafi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86 (1997) 1-12
15. Heikkila T., Salonen J., Tuura J., Hamdy M.S., Mul G., Kumar N., Salmi T., Murzin D.Yu., Laitinen L., Kaukonen A.M., Hirvonen J., and Lehto V.-P. Mesoporous silica material TUD-1 as drug delivery system. Int. J. Pharm. 331 (2007) 133-138
16. Jamzad S., and Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-technical note. AAPS Pharm. Sci. Tech. 7 (2006) E1-E6
17. Jmol. An open-source java viewer for chemical structures in 3D. Available via http://jmol.sourceforge.net/ (accessed on August 15, 2007).
18. Jounela A., Pentikainen P., and Sothmann A. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8 (1975) 365-370
19. Kaushal A.M., Gupta P., and Bansal A.K. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 133-193
20. Lin-Vien D., Colthup N.B., Fateley W.G., and Grasselli J.G. The Handbook of Infrared and Raman Characteristic Frequencies of Organic Molecule (1991), Academic Press Inc., San Diego
21. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystalline danzol in beagle dogs. Int. J. Pharm. 125 (1995) 91-97
22. Madieh S., Simone M., Wilson W., Mehra D., and Augsburger L. Investigation of drug-porous adsorbent interactions in drug mixtures with selected porous adsorbents. J. Pharm. Sci. 96 (2007) 851-863
23. McGinity J.W., and Harris M.R. Increasing dissolution rates of poorly soluble drugs by adsorption to montmorillonite. Drug Dev. Ind. Pharm. 6 (1980) 35-48
24. Monkhouse D.C., and Lach J.L. Use of adsorbents in enhancement of drug dissolution I. J. Pharm. Sci. 6 (1972) 1430-1435
25. Monkhouse D.C., and Lach J.L. Use of adsorbents in enhancement of drug dissolution II. J. Pharm. Sci. 6 (1972) 1435-1441
26. Munoz A., Guichard J.P., and Reginault Ph. Micronized fenofibrate. Atherosclerosis 110 (1994) S45-S48
27. Patel A.R., and Vavia P.R. Effect of polymer on solubilization of fenofibrate by cyclodextrin complexation. J. Inclusion Phenomena Macrocyclic Chem. 56 (2006) 247-251
28. Pikal M.J., Lukes A.L., Lang J.E., and Gaines K. Quantative crystallinity determinations for β-lactam antibiotics by solution calorimetry: correlation with stability. J. Pharm. Sci. 67 (1978) 767-773
29. Rasenack N., and Muller B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 19 (2002) 1894-1900
30. Sheu M.T., Yeh C.M., and Sokoloski T.D. Characterization and dissolution of fenofibrate solid dispersion systems. Int. J. Pharm. 103 (1994) 137-146
31. Smirnova I., Suttiruengwong S., Seiler M., and Arlt W. Dissolution rate enhancement by adsorption of poorly soluble drugs on silica aerogels. Pharm. Dev. Tech. 9 (2004) 443-452
32. U.S. Department of Health and Human Services Food and Drug administration. Guidance for industry Q1A stability testing of new drug substances and products. Available via http://www.fda.gov/cder/guidance/index.htm (accessed on June 20, 2007).
33. U.S. Department of Health and Human Services Food and Drug administration. Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. Available via http://www.fda.gov/cder/Guidance/1713bp1.pdf (accessed on June 20, 2007).
34. United States Pharmacopeial Convention. In Vitro and In Vivo Evaluation of Dosage Forms (2005), United States Pharmacopeial Convention Inc., USP 28, Rockville, MD p. 1088
35. Vogt M., Kunath K., and Dressman J.B. Dissolution enhancement of fenofibrate by micronization, cogrinding, and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm. 68 (2008) 283-288
36. Wang L., Cui F.D., and Sunada H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using melt mixing method. Chem. Pharm. Bull. 54 (2006) 37-43
37. Wishart D.S., Konx C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. Drug bank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 1 (2006) D668-D672
38. Zhou A., Zhang Geoff G.Z., Law D., Grant David J.W., and Schmitt E.A. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci. 1 (2002) 1863-1872